Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Related Posts

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494

Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE Jr, Calais J. FAP Expression in Renal Tumors Assessed[...]

Akebia Saponin D Targeting Ubiquitin Carboxyl-Terminal Hydrolase 4 Promotes Peroxisome Proliferator-Activated Receptor Gamma Deubiquitination and Activation of Brown Adipose Tissue Thermogenesis in Obesity

Chen L, Liu DH, Li YX, Yang S, Jia WH, Peng L, Liu HL, Wang XB, Hu B, Wang YC, Pan C, Lusis AJ, Liu[...]

The relationship between blood eosinophil count and cardiovascular outcomes in prediabetes and diabetes patients with acute coronary syndrome: insights from a large Asian cohort analysis

Feng X, Liu Y, Qin H, Zhao S, Yang J, Yang S, Zhou Z, Liu Y, Wang Z, Shi D, Zhou Y, Guo Q. The[...]